# Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B

> **NCT00524173** · PHASE2 · TERMINATED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 35 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Tenofovir & Emtricitabine
- **DRUG:** Tenofovir

## Key facts

- **NCT ID:** NCT00524173
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08-29
- **Primary completion:** 2017-02-16
- **Final completion:** 2017-02-16
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00524173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00524173, "Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00524173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*